😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Jasper Therapeutics COO sells $21.7k in company stock

Published 06/12/2024, 09:42 PM

REDWOOD CITY, CA – Jasper Therapeutics, Inc. (NASDAQ:JSPR) Chief Operating Officer Jeetinder Singh Mahal has sold 900 shares of the company's common stock, according to the latest SEC filings. The transaction, which took place on June 12, 2024, netted a total of $21,739 for the executive, with shares sold at an average price of $24.155. The sale occurred in multiple transactions at prices ranging from $23.975 to $24.555.

The same filing also disclosed that Mahal acquired 900 shares of Jasper Therapeutics' voting common stock on the same date at a price of $7.10 per share, amounting to a total transaction value of $6,390. This transaction was part of an equity incentive plan, as indicated by the accompanying footnote in the SEC filing.

Jasper Therapeutics, a company specializing in biological products, has seen its executives engage in transactions that are often of interest to investors, as they may provide insights into the leadership's perspective on the company's value. These transactions are reported in compliance with SEC regulations and are publicly disclosed for investor transparency.

Investors and followers of Jasper Therapeutics can access full details of these transactions upon request to the SEC, the company, or the security holder of the issuer. The transactions are part of a pre-arranged trading plan under Rule 10b5-1, which allows insiders to set up a predetermined plan for buying or selling stock at a time when they are not in possession of material non-public information.

Jeetinder Singh Mahal's recent transaction brings his total direct ownership in Jasper Therapeutics to 25,009 shares following the sale. The executive's activities in the market are closely watched, as changes in insider holdings can be indicative of a company's future prospects.

In other recent news, Jasper Therapeutics has seen significant developments, including executive changes, stockholder approvals, and the initiation of new clinical trials. The biopharmaceutical company recently approved new equity plans and established amended employment agreements with key executives, following its Annual Meeting. In addition, Jasper Therapeutics plans to initiate a Phase 1b/2a clinical trial for its drug briquilimab in asthma patients, expected to commence in Q4 2024.

Several analyst firms have provided coverage on Jasper Therapeutics, with H.C. Wainwright initiating a Buy rating, and Evercore ISI, RBC Capital, and TD Cowen all giving the company an Outperform rating. These ratings reflect the potential of Jasper Therapeutics' drug briquilimab for treating various conditions.

These recent developments highlight Jasper Therapeutics' commitment to governance, leadership stability, and innovative efforts in the biopharmaceutical industry.

InvestingPro Insights

Amidst the recent insider transaction by Jasper Therapeutics' COO, Jeetinder Singh Mahal, the company's financial health and market performance provide additional context for investors. According to InvestingPro, Jasper Therapeutics holds more cash than debt on its balance sheet, which can be a sign of financial stability. However, the company is also quickly burning through cash, which raises questions about its long-term financial management and sustainability.

The market has responded to Jasper Therapeutics with significant volatility. The company's stock price has experienced a substantial rise over the last six months, with a 466.71% increase, and a strong return over the last month at 15.61%. Despite this impressive short-term performance, analysts are skeptical about the company's profitability in the near future, as they do not anticipate Jasper Therapeutics will be profitable this year.

InvestingPro data reveals that Jasper Therapeutics has a market capitalization of $362.35 million, with a negative P/E ratio of -4.38, reflecting the company's current lack of earnings. Additionally, the firm's return on assets for the last twelve months as of Q1 2024 stands at -48.3%, indicating challenges in generating profit from its assets.

For investors seeking a deeper dive into Jasper Therapeutics' financials and market performance, InvestingPro offers a comprehensive set of additional tips. There are currently 10 additional InvestingPro Tips available, which can be accessed by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. These insights may prove invaluable in forming a more complete investment thesis around the company's stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.